Author(s):
Manjunatha E, Palaksha M N
Email(s):
palaksha.mn@gmail.com
DOI:
10.52711/2321-5836.2025.00016 
Address:
Manjunatha E1, Palaksha M N2*
1Department of Pharmaceutical Chemistry, Sree Siddaganga College of Pharmacy, Tumkur, Karnataka, India.
2Principal, Aadya College of Phamacy, Chitradurga. Karnataka, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 2,
Year - 2025
ABSTRACT:
A metabolic disease with several etiologies, diabetes mellitus (DM) is typified by persistent hyperglycemia and abnormalities in the metabolism of fat, protein, and carbohydrates. The world's most common cause of death is diabetes mellitus. Fructose is a simple sugar present in fruits and honey and is responsible for their sweet taste. Fructose a monosaccharide is from sucrose or table sugar, source of which is from sugar cane and sugar beets. A simple Monosaccharide, Glucose is available from plants, is one of the three edible monosaccharaides, along with fructose and galactose, which are absorbed directly into the bloodstream during digestion. Though they exhibit structures similarity, glucose and fructose are undergoes different metabolism reactions. Insulin resistance is linked to the advancement of type 2 diabetes mellitus and a number of other malfunctions in the normal functioning of the body, including obesity, hypertension and cardiovascular disease. In the last few decades, type 2 diabetes and obesity have become epidemics around the world and epidemiological and metabolic research suggests that the two diseases are related by Insulin resistance. The disruption of free fatty acid (FFA) metabolism is now recognized as a primary contributor to whole body Insulin resistance, including skeletal muscle Insulin resistance. Acute exposure to free fatty acids (FFAs) and high dietary fat consumption are strongly associated with the etiology of muscle insulin resistance. In this review we are exploring the underlying processes by which fructose causes Insulin resistance and suggest actions based on these associations that have potential impact.
Cite this article:
Manjunatha E, Palaksha M N. The Impact of Fructose on Diabetes Mellitus: Insights and Implications. Research Journal of Pharmacology and Pharmacodynamics.2025;17(2):102-6. doi: 10.52711/2321-5836.2025.00016
Cite(Electronic):
Manjunatha E, Palaksha M N. The Impact of Fructose on Diabetes Mellitus: Insights and Implications. Research Journal of Pharmacology and Pharmacodynamics.2025;17(2):102-6. doi: 10.52711/2321-5836.2025.00016 Available on: https://rjppd.org/AbstractView.aspx?PID=2025-17-2-3
REFERENCES:
1. Osler W. The Principles and Practice of Medicine. 2nd ed. 1895.
2. Cory S, Ussery-Hall A, Griffin-Blake S, et al. Prevalence of selected risk behaviors and chronic diseases and conditions–steps communities, United States, 2006–2007. MMWR Morb Mortal Wkly Rep. 2010; 59(8): 1–37.
3. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: The Framingham Heart Study. Circulation. 2006; 113(25): 2914–2918.
4. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000; 106(4): 473–481.
5. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004; 79(1): 31–39.
6. Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009; 30(1): 96–116.
7. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics. 2007; 8(2): 113–128.
8. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004; 79: 537–543.
9. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. JAMA. 1983; 254(23): 3245–3248.
10. Cannon G, Einzig H, Heald FP. The impact of fructose on human blood glucose and insulin response. Diabetes Care. 1986; 9(1): 1–5.
11. Crapo PA, Kolterman OG. The metabolic effects of dietary fructose in diabetic and normal individuals. Diabetes Care. 1984; 7(5): 462–472.
12. Henry RR, Crapo PA, Thorburn AW. Current issues in fructose metabolism. Annu Rev Nutr. 1991; 11: 21–39.
13. Jenkins DJA, Wolever TMS, Taylor RH, et al. Glycemic index of foods: A physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981; 34(3): 362–366.
14. Swan MD, Shultz TD, Brigham SA, McGill JB. Comparative effects of sucrose and fructose on glucose and insulin levels in normal and diabetic patients. Lancet. 1966; 287(7432): 457–459.
15. Ludwig DS, Pereira MA, Kroenke CH, et al. Dietary fiber, weight gain, and cardiovascular risk factors in young adults. JAMA. 1999; 282: 1539–1546.
16. Kellett GL, Brot-Laroche E. Apical GLUT2: a major pathway of intestinal sugar absorption. Diabetes. 2005; 54: 3056–3062.
17. Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab. 2005; 2: 1–14.
18. Straub SG, Sharp GW. Glucose-stimulated signalling pathways in biphasic insulin secretion. Diabetes Metab Res Rev. 2002; 18: 451–463.
19. Frayn KN, Kingman SM. Dietary sugars and lipid metabolism in humans. Am J Clin Nutr. 1995; 62(1): 250S–263S.
20. Le GM, Tobin V, Stolarczyk E, et al. Sugar sensing by enterocytes combines polarity, membrane bound detectors and sugar metabolism. J Cell Physiol. 2007; 213: 834–843.
21. Leturque A, Brot-Laroche E, Le GM. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab. 2009; 296–992.
22. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010; 7:251–264.
23. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010; 7(5): 251–264.
24. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010; 7(5): 251–264.
25. Khan A, Watts GF. Fructose and glucose: A metabolic perspective. Nutr Metab. 2015; 12(1): 1–9.
26. Tappy L, Lê KA. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care. 2010; 13(4): 434–438.
27. Hughes J, Riddell MC. Fructose consumption and its impact on metabolic syndrome and related disorders. Curr Diabetes Rep. 2013; 13(5): 665–671.
28. George JA, Seshadri P. High fructose corn syrup: A review of the health implications. J Clin Nutr. 2010;92(4):897–904.
29. Tappy L, Lê KA. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care. 2010; 13(4): 434–438.
30. Schröder H, Marquez D. Comparative effects of fructose and glucose on metabolic syndrome features in animal models. Nutr Rev. 2014; 72(10): 655–667.
31. Havel PJ. Dietary fructose: Implications for dyslipidemia, hypertension, and obesity. Curr Opin Lipidol. 2005; 16(1): 12–19.
32. Tappy L, Lê KA. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care. 2010; 13(4): 434–438.
33. Lustig RH, Nadeau JH. The role of fructose in the development of obesity and metabolic syndrome: A review. Metabolism. 2014; 63(5): 651–661.
34. Stanhope KL, Havel PJ, Hagan LL. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2008; 88(6): 1733–1739.
35. Palaksha MN, Tamizh MT, Manjunatha E, Kumar GS. Comparative study of In-Vivo effects of Glipizide and Metformin HCl on plasma concentration of Aminophylline in healthy rabbits. Asian J Pharma Res. 2020 Jun 1; 10(2).
36. Manjunatha E, Nandeesh R, Ahmed SM. Antiulcer and ulcer healing potential of some medicinal plants: A review. Res J Pharmacog and Phytochem. 2022; 14(1): 37-42.
37. Mahesh Babasaheb Kolap, Nandini Maruti Bhise, Nisha Vasant Poojary, Rajesh Keshav Bhadke. Diabetes mellitus A Case Study. Res J Pharmacol Pharmacodynamics 2023; 15(1): 6-8.
38. Mansuri Sajid, Goswami Raksha, Jain Neetesh Kumar. In vitro Alpha glucosidase and Aldolase reductase Inhibitory activity of Holoptelea integrifolia. Res J Pharmacol Pharmacodynamics. 2021; 13(2): 35-40.
39. Aditya Mathur, Shweta Asthana, Samir Patra, Pulak Jana. A Review on Current Type-2 Diabetes Mellitus Treatment by selected Phytoconstituents. Res J Pharmacol Pharmacodynamics. 2023; 15(4): 205-1.
40. Indrayani D. Raut, Akshada N. Kakade, Jadhav Snehal, Jadhav Priyanka, Kabir Amruta. Survey on Antidiabetic Drugs. Res. J. Pharmacol Pharmacodynamics. 2017; 9(1): 10-12.
41. Bhavimani Guru, Nitin M. Pharmacological Studies on Drug-Drug Interactions between Antidiabetic Drug (Glibenclamide) and Selective Anti-HIV Drug (Lamivudine) in Rats and Rabbits. Res. J. Pharmacology & Pharmacodynamics. 2017; 9(3): 117-121
42. Vadivelan R, Dhanabal SP, Raja Rajeswari, Shanish A, Elango K, Suresh B. Oxidative Stress in Diabetes- A Key Therapeutic Agent. Research J Pharmacol & Pharmacodynamics. 2010; 2(3): 221-227.
43. SM Bhanushali, KM Modh, IS Anand, CN Patel, JB Dave. Novel Approaches for Diabetes Mellitus: A Review. Res J. Pharmacol & Pharmacodynamics. 2010; 2(2): 141-147.
44. AR Umarkar, AK Raut, SS Sonone, SS Pawar, RS Deshmukh, NV Bharude. Dibetes in India: A Review. Res J Pharmacology & Pharmacodynamics. 2011; 3(6): 345-352.
45. Vandna Dewangan, Himanshu Pandey. Pathophysiology and Management of Diabetes: A Review. Res J Pharmacol & Pharmacodynamics.2016; 8(3): 219-222.